Abstract
The Department of Health’s new guidelines for its ‘indicative prescribing’ scheme in general practice1 mean that Family Health Service Authorities (FHSAs) will be encouraging GPs to achieve rational, cost-effective prescribing, especially where prescribing costs have been well above, or well below, average. GPs will get help from various sources including, Prescribing Analyses and Costs (PACT) data and from the new local prescribing advisers, but they will still have to evaluate the many new medicines each year. Because of this, we shall next year publish short notes on new products soon after they are introduced. We will aim to assess evidence cited at their launch, without precluding more detailed review later. It is thus timely to outline the key stages by which a new medicine reaches the market. This article discusses the strengths and some weaknesses of the present system, and the changes foreseen as European Community rules begin to work.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
